Read this article in:
Netherlands-based Protyon, a company that guides clinicians towards personalised treatment and enhancing the quality of life for patients, announced on Thursday, May 11, that it has raised €600K in a pre-seed round of funding.
According to Protyon, it aims to help create a future in which every patient’s treatment includes a molecular visualisation of the illness, allowing medical professionals to select the “best” available therapy.
The raised capital will be used to expand Protyon’s technology and create a SaaS business model.
Investors in this round
The investment came from Dutch-based LUMO Labs and NOM, the regional development agency for the northern Netherlands.